ClinicalTrials.gg
CompletedNCT07936942Updated Nov 13, 2026

Quality of Life and Uremic Toxins in HDx

An interventional study of Medium Cut-Off Dialyzer for Expanded Hemodialysis in End Stage Kidney Disease (ESKD), sponsored by Mackay Memorial Hospital. Completed at 1 site in Taiwan. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Mackay Memorial Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Mar 2024, registered Nov 2026).
Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies in Kidney Failure, Chronic with a site in Taiwan — 11 open to participants now, 13 under way, 2 of them phase 3. Kidney Failure, Chronic · Taiwan.

Enrollment
51st of 52
23 · median 80
Started
2024
with 3 others
No phase
25 of 70
2 open now
Registered
70th of 70
by date

Among the 70 studies in Kidney Failure, Chronic with a site in Taiwan, this one is the 51st largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2024, is one of 25 with no phase, and was the 70th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

11 of the 70 studies in Kidney Failure, Chronic with a site in Taiwan are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Kidney Failure, Chronic with a site in Taiwan, or all of them as a file.
02

Study summary

Expanded hemodialysis (HDx) is a dialysis treatment designed to improve the removal of certain waste products from the blood. However, its effects on health-related quality of life and blood levels of uremic toxins in patients receiving long-term hemodialysis remain uncertain.

This study aimed to evaluate changes in quality of life and uremic toxin levels after switching from conventional hemodialysis to HDx. Patients who had been receiving maintenance hemodialysis for at least 10 years underwent HDx for three months. Quality of life and blood levels of selected uremic toxins were assessed before and after the treatment period.

The study aimed to determine whether switching to HDx was associated with changes in patients' quality of life and uremic toxin profiles.

Read the detailed description

This was a single-center, single-arm, before-and-after study evaluating the effects of expanded hemodialysis (HDx) on health-related quality of life and uremic toxin profiles in patients undergoing long-term maintenance hemodialysis.

Eligible participants were adults who had received maintenance hemodialysis three times weekly for at least 10 years. Participants were switched from conventional hemodialysis to HDx using a medium cut-off dialyzer for three months.

Health-related quality of life was assessed at baseline and after three months using the RAND 36-Item Health Survey (RAND-36). Blood samples were collected at both time points to evaluate selected middle-molecule biomarkers and protein-bound uremic toxins, including beta-2 microglobulin, free light chains, indoxyl sulfate, and p-cresyl sulfate. Additional laboratory and dialysis adequacy parameters were also evaluated.

Changes between baseline and three months were analyzed using paired statistical comparisons. As this was a single-arm study without a concurrent control group, the findings were intended to describe changes associated with switching to HDx rather than establish a causal treatment effect.

03

Conditions studied

  • End Stage Kidney Disease (ESKD)

Keywords

  • Expanded hemodialysis
  • Medium cut-off dialyzer
  • Maintenance hemodialysis
  • Health-related quality of life
  • Uremic toxins
  • Protein-bound uremic toxins
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • Patients receiving maintenance hemodialysis three times weekly for at least 10 years.
  • Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Active .
  • Other major organ failure.
  • History of major surgery within the preceding 3 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Expanded Hemodialysis (HDx)

    Participants receiving long-term maintenance hemodialysis were switched from conventional hemodialysis to expanded hemodialysis (HDx) using a medium cut-off dialyzer for three months. Hemodialysis was performed three times weekly. Health-related quality of life and uremic toxin levels were assessed at baseline and after the three-month HDx intervention.

    Device: Medium Cut-Off Dialyzer for Expanded Hemodialysis

Interventions

  • DeviceMedium Cut-Off Dialyzer for Expanded Hemodialysis

    Participants were switched from conventional maintenance hemodialysis to expanded hemodialysis (HDx) using a medium cut-off (MCO) dialyzer for three months. Hemodialysis was performed three times weekly, with treatment sessions lasting 180-240 minutes, blood flow rates of 200-300 mL/min, and a dialysate flow rate of 500 mL/min. Dialysis prescriptions were adjusted according to individual clinical needs. Health-related quality of life and uremic toxin profiles were assessed before and after the three-month intervention.

06

What researchers measure

Primary outcomes

  1. Change in Health-Related Quality of Life Measured by RAND-36

    Health-related quality of life was assessed using the RAND 36-Item Health Survey 1.0 (RAND-36) at baseline and after three months of expanded hemodialysis. The questionnaire evaluates eight health domains: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, bodily pain, and general health. Each domain is scored from 0 to 100, with higher scores indicating better health status. Changes from baseline to three months were assessed for each domain separately. No overall composite score was calculated.

    Time frame: Baseline and Month 3

Secondary outcomes

  1. Change in Intact Parathyroid Hormone Concentration

    Time frame: Baseline and Month 3

  2. Change in Beta-2 Microglobulin Concentration

    Time frame: Baseline and Month 3

  3. Change in Interleukin-6 Concentration

    Time frame: Baseline and Month 3

  4. Change in Kappa Free Light Chain Concentration

    Time frame: Baseline and Month 3

  5. Change in Lambda Free Light Chain Concentration

    Time frame: Baseline and Month 3

  6. Change in Total Indoxyl Sulfate Concentration

    Time frame: Baseline and Month 3

  7. Change in Free Indoxyl Sulfate Concentration

    Time frame: Baseline and Month 3

  8. Change in Total p-Cresyl Sulfate Concentration

    Time frame: Baseline and Month 3

  9. Change in Free p-Cresyl Sulfate Concentration

    Time frame: Baseline and Month 3

07

Study locations

1 site
  • MacKay Memorial Hospital
    Taipei, Taiwan
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared with external researchers because the study involves sensitive patient-level clinical information and no external individual participant data sharing is planned under the current study protocol.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jun 2024, 3 months.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's 3 months is below that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 13, 2026
StartActual
Mar 1, 2024
Primary completionActual
Jun 30, 2024
CompletionActual
Jul 30, 2024
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07936942
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Mar 1, 2024
Primary completion
Jun 30, 2024
Completion
Jul 30, 2024
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion